UPDATE 1-Panel recommends Merck & Co continue cholesterol drug study
November 13, 2015 at 08:34 AM EST
Nov 13 (Reuters) - Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib.
